Merck & Company Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: MRK Category:


Merck delivered a mediocre result but the company has made some promising developments in oncology as well as its new HIV collaboration with Gilead. The company has a solid pipeline in place and some key revenue drivers such as its HPV vaccine, Gardasil which is expected to generate close to $11 billion in revenues by 2026, demonstrating a double-digit growth. Another vaccine expected to generate strong growth is the company’s measles-mumps-rubella vaccine where it practically has no competition. The management has also carried out strategic acquisitions such as the $2.75 billion worth ValesBio to further boost its oncology portfolio. Overall, despite the tepid result, the company appears to have a strong future upside and deserves an ‘Outperform’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!